June 27, 2024
On June 26, the Minnesota Department of Health (MDH) released an initial list of drugs that are priced significantly higher than their listed cost.
The list includes drug families with drug products that meet two criteria: 1) the average claims paid amount was more than $100; and 2) the average claims paid amount is 125% of the manufacturer’s list price as of the date in which the claim was incurred.
MDH estimates that 37% of all retail drug products dispensed for commercially insured Minnesotans, per the Minnesota All Payer Claims Database (APCD) in 2022, meet these criteria. This amounts to annual spending of $345 million over manufacturer list prices and represents 54% of the total amount paid for these drug products before rebates.
The inaugural list features 10 drug families containing a total of 364 drug products from 76 manufacturers. These 10 drug families include all pharmaceutically equivalent drug products on the market for comparison, with drug products across all strengths and package sizes. MDH selected the drug families having the greatest absolute difference between the total claims paid amount and the total list price. The diversity of drug families on this list will allow MDH to better understand the prescription drug supply chain, including intermediary price increases and rebate dynamics.
The list is the result of legislation passed in 2023 by the Minnesota Legislature. Called the Prescription Drug Price Transparency Act, the law requires new reporting from drug manufacturers, pharmacy benefit managers (PBMs), wholesalers, and pharmacies on drugs of substantial public interest.
Reporting entities will have approximately 90 days to report (notifications will be sent 30 or more days after the list release date; reports are due 60 days after notifications are sent).
MDH will continue to release updates on implementation on the MDH Rx Price Transparency website. For questions, please email health.rx@state.mn.us
December 4, 2025
On December 4, Minnesota Management and Budget (MMB) released its budget forecast for the 2026-27 biennium, showing a short-term budget surplus of $2.5 billion for the current biennium, but warned of a long-term $2.96 billion deficit for the 2028-29 biennium.
December 4, 2025
On December 2, the Vaccine Integrity Project (VIP) released a study on the safety, effectiveness, and public health impact of hepatitis B virus (HBV) vaccinations at birth.
December 4, 2025
The Minnesota Department of Commerce (DOC) is now accepting public comments regarding proposed legislation to mandate insurance coverage of certain treatments.